Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
Fulgent Genetics (NASDAQ: FLGT) will release its Q1 2021 financial results on May 6, 2021, after market close. A conference call for investors will follow at 4:30 PM ET, hosted by CEO Ming Hsieh, CFO Paul Kim, and CCO Brandon Perthuis. The call can be accessed via a live audio webcast or by dialing (800) 353-6461 with code 9490797. Fulgent’s advanced technology platform offers a wide array of genetic testing solutions, including RT-PCR tests for COVID-19, with Emergency Use Authorization from the FDA.
- Upcoming Q1 2021 financial results may show progress in revenue and testing volume.
- Strong market position due to comprehensive genetic testing solutions and flexibility for clients.
- None.
TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its first quarter 2021 financial results after the market closes on Thursday May 6, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (800) 353-6461 using the confirmation code 9490797. An audio replay will be available in the Investors section of the company’s website.
About Fulgent Genetics
Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. The Company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
FAQ
When will Fulgent Genetics release its Q1 2021 financial results?
What time is the Fulgent Genetics conference call for Q1 2021 results?
How can I access the Fulgent Genetics Q1 2021 financial results call?
What COVID-19 testing solutions does Fulgent Genetics offer?
